

















## NIRMATRELVIR/RITONAVIR (PAXLOVID) PHARMACIST COUNSELLING CHECKLIST

\*This checklist is intended for use by pharmacists as a quick reference guide and should not be regarded as a substitute for clinical judgement and patient-specific counselling as required by the Health Professions Act. Documentation or filing of this form is not required.

Overview	☐ Nirmatrelvir/ritonavir (Paxlovid) is used for the treatment of mild to
	moderate COVID-19 in eligible patients to prevent hospitalizations due to
	<b>COVID-19</b> . This medication does <b>not</b> prevent future infections.
	☐ Nirmatrelvir prevents viral replication, and ritonavir prevents breakdown of
	nirmatrelvir.
5 1	☐ The drug should be started <b>within 5 days of symptom onset</b> to be effective.
Dosage and	☐ Nirmatrelvir/ritonavir should be taken by mouth, twice a day, for 5 days
Administration	☐ Each daily blister has separated parts for the morning dose (the yellow side)
	and evening dose (the blue side).
	☐ Each dose consists of 3 tablets:
	2 nirmatrelvir 150 mg (pink tablets), and
	1 ritonavir 100 mg (white tablet)
	☐ Take all morning tablets at the same time and take all the evening tablets
	at the same time.
	☐ Take the medication with or without food.
	☐ Complete the entire 5-day course, even if you feel better.
	$\Box$ If moderate renal impairment (eGFR ≥ 30 mL/min to < 60 mL/min):
	Reduced dose: Take 1 tablet of nirmatrelvir 150 mg and 1 tablet of
	ritonavir 100 mg every 12 hours for 5 days.
Side effects	☐ Most side effects are <b>mild</b> . Common side effects may include altered sense
	of taste, diarrhea, nausea, vomiting, muscle aches, headache, and increased
	blood pressure.
	Other side effects that are not listed may also occur.
	☐ Call the pharmacist if worried about a side effect or notice other side effects
	that are not listed. (Note: If patients report an adverse reaction to
	nirmatrelvir/ritonavir, pharmacist should report the reaction to Health
	Canada: https://www.canada.ca/en/health-canada/services/drugs-health-
	products/medeffect-canada/adverse-reaction-reporting.html)
D	☐ Describe symptoms of an <b>allergic reaction</b> and management plan.
Drug	☐ Provide patient-specific drug-interaction education and management
Interactions	strategies.
	☐ If possible, do not start any new medications, OTCs, herbals, supplements,
	etc. Call the pharmacist prior to initiation of any new drug or product.



















	Dravida directions on how to manage any modified modications once
	☐ Provide directions on how to manage any modified medications once
	nirmatrelvir/ritonavir treatment finishes or the treatment is stopped early.
	☐ Acetaminophen, ibuprofen, naproxen, and dextromethorphan are <b>safe</b> to
	take with nirmatrelvir/ritonavir if these medications are otherwise safe for
	patient to take.
Monitoring	☐ Call 911, go to an urgent care clinic, or emergency department if: having
	difficulty breathing, chest pain, difficulty drinking or swallowing, feeling very
	sick, feeling confused, or experiencing any loss of consciousness
	☐ Call 811 if worsened symptoms while taking nirmatrelvir/ritonavir or not
	feeling better after 5 days of taking nirmatrelvir/ritonavir.
	☐ Provide patient-specific monitoring parameters and plan.
	☐ Inform patient that the pharmacist will call for follow up in 6-10 days.
Missed dose	
	☐ ≤ 8 hours: Take missed dose as soon as possible, and resume normal dosing
protocol	schedule thereafter.
	$\square$ > 8 hours: Skip missed dose and take the next dose at the regularly
	scheduled time, then resume normal dosing schedule thereafter.
	$\square$ Do not double the dose to make up for a missed dose.
Storage	$\square$ Store at room temperature, not in the bathroom or kitchen.
	☐ Keep out of the reach of children.
Infection	☐ <b>Follow PHO orders</b> , even if feeling better. (See site for updated PHO orders:
control	https://www2.gov.bc.ca/gov/content/covid-19/info/restrictions)
strategies	☐ COVID-19 vaccine initiation or completion of series/booster is encouraged,
	as appropriate. (Last update from BCCDC on Nov 2021 indicates patients can
	receive COVID-19 vaccines as soon as they feel better and no longer have to
	isolate. http://www.bccdc.ca/Health-Info-Site/Documents/COVID-
	19 vaccine/Vaccination After COVID19.pdf)
Resources (for	BC COVID Therapeutics Committee (CTC) Clinical Practice Guide, Practice
pharmacists)	Tools: http://www.bccdc.ca/health-professionals/clinical-resources/covid-19-
	<u>care/clinical-care/treatments</u>
	BCCDC Patient Information on nirmatrelvir/ritonavir:
	http://www.bccdc.ca/Health-Info-Site/Documents/COVID-
	19 Treatment/Patient information-PAXLOVID.pdf
	BC-Cfe Guidelines for the use of Paxlovid® and ARVs:
	http://www.bccfe.ca/therapeutic-guidelines/bc-cfe-guidelines-use-
	paxlovid-and-arvs
	<ul> <li>University of Liverpool COVID-19 Drug Interaction checker:</li> </ul>
	https://www.covid19-druginteractions.org/checker
i e	
	<ul> <li>Health Canada Product Monograph:</li> <li>https://pdf.hres.ca/dpd pm/00064313.PDF</li> </ul>